Global Durvalumab Report Thumbnail

Global Durvalumab Market by Type (2.4mL Injection, 10mL Injection), By Application (Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Other) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028

  • Report ID: PH-19939
  • Author: Up Market Research
  • Rating: 4.6
  • Total Reviews: 50
  • No. Of Pages: 222
  • Format:
  • Pub. Date: 2021-04-04
  • Share:

Up Market Research published a new report titled “Durvalumab Market research report which is segmented by Types (2.4mL Injection, 10mL Injection), By Applications (Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Other), By Players/Companies Medimmune (AstraZeneca)”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.


Report Scope

Report AttributesReport Details
Report TitleDurvalumab Market Research Report
By Type2.4mL Injection, 10mL Injection
By ApplicationLocally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Other
By CompaniesMedimmune (AstraZeneca)
Regions CoveredNorth America, Europe, APAC, Latin America, MEA
Base Year2020
Historical Year2018 to 2019 (Data from 2010 can be provided as per availability)
Forecast Year2028
Number of Pages222
Number of Tables & Figures156
Customization AvailableYes, the report can be customized as per your need.

The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.


Global Durvalumab Industry Outlook

Global Durvalumab Market Report Segments:

The market is segmented by Type 2.4mL Injection, 10mL Injection and By Application Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Other.


Some of the companies that are profiled in this report are:

  1. Medimmune (AstraZeneca)

Durvalumab Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.


Key Benefits for Industry Participants & Stakeholders:

  • Industry drivers, restraints, and opportunities covered in the study
  • Neutral perspective on the market performance
  • Recent industry trends and developments
  • Competitive landscape & strategies of key players
  • Potential & niche segments and regions exhibiting promising growth covered
  • Historical, current, and projected market size, in terms of value
  • In-depth analysis of the Durvalumab Market

Overview of the regional outlook of the Durvalumab Market:

Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.


Durvalumab Market Overview

Highlights of The Durvalumab Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of Durvalumab Market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2028.
  5. Developments and trends in the market.
  6. By Type:

                1. 2.4mL Injection

                2. 10mL Injection

       7. By Application:

                1. Locally Advanced Urothelial Carcinoma

                2. Metastatic Urothelial Carcinoma

                3. Other

  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Durvalumab Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.


How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Durvalumab Market Statistics

Reasons to Purchase the Durvalumab Market Report:

  • The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
  • Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
  • Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
  • The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
  • Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Durvalumab Market Overview
   4.1 Introduction 
      4.1.1 Market Taxonomy 
      4.1.2 Market Definition 
      4.1.3 Macro-Economic Factors Impacting the Market Growth 
   4.2 Durvalumab Market Dynamics 
      4.2.1 Market Drivers 
      4.2.2 Market Restraints 
      4.2.3 Market Opportunity 
   4.3 Durvalumab Market - Supply Chain Analysis 
      4.3.1 List of Key Suppliers 
      4.3.2 List of Key Distributors 
      4.3.3 List of Key Consumers 
   4.4 Key Forces Shaping the Durvalumab Market 
      4.4.1 Bargaining Power of Suppliers 
      4.4.2 Bargaining Power of Buyers 
      4.4.3 Threat of Substitution 
      4.4.4 Threat of New Entrants 
      4.4.5 Competitive Rivalry 
   4.5 Global Durvalumab Market Size & Forecast, 2018-2028 
      4.5.1 Durvalumab Market Size and Y-o-Y Growth 
      4.5.2 Durvalumab Market Absolute $ Opportunity 


Chapter 5 Global Durvalumab Market Analysis and Forecast by Type
   5.1 Introduction
      5.1.1 Key Market Trends & Growth Opportunities by Type
      5.1.2 Basis Point Share (BPS) Analysis by Type
      5.1.3 Absolute $ Opportunity Assessment by Type
   5.2 Durvalumab Market Size Forecast by Type
      5.2.1 2.4mL Injection
      5.2.2 10mL Injection
   5.3 Market Attractiveness Analysis by Type

Chapter 6 Global Durvalumab Market Analysis and Forecast by Applications
   6.1 Introduction
      6.1.1 Key Market Trends & Growth Opportunities by Applications
      6.1.2 Basis Point Share (BPS) Analysis by Applications
      6.1.3 Absolute $ Opportunity Assessment by Applications
   6.2 Durvalumab Market Size Forecast by Applications
      6.2.1 Locally Advanced Urothelial Carcinoma
      6.2.2 Metastatic Urothelial Carcinoma
      6.2.3 Other
   6.3 Market Attractiveness Analysis by Applications

Chapter 7 Global Durvalumab Market Analysis and Forecast by Region
   7.1 Introduction
      7.1.1 Key Market Trends & Growth Opportunities by Region
      7.1.2 Basis Point Share (BPS) Analysis by Region
      7.1.3 Absolute $ Opportunity Assessment by Region
   7.2 Durvalumab Market Size Forecast by Region
      7.2.1 North America
      7.2.2 Europe
      7.2.3 Asia Pacific
      7.2.4 Latin America
      7.2.5 Middle East & Africa (MEA)
   7.3 Market Attractiveness Analysis by Region

Chapter 8 Coronavirus Disease (COVID-19) Impact 
   8.1 Introduction 
   8.2 Current & Future Impact Analysis 
   8.3 Economic Impact Analysis 
   8.4 Government Policies 
   8.5 Investment Scenario

Chapter 9 North America Durvalumab Analysis and Forecast
   9.1 Introduction
   9.2 North America Durvalumab Market Size Forecast by Country
      9.2.1 U.S.
      9.2.2 Canada
   9.3 Basis Point Share (BPS) Analysis by Country
   9.4 Absolute $ Opportunity Assessment by Country
   9.5 Market Attractiveness Analysis by Country
   9.6 North America Durvalumab Market Size Forecast by Type
      9.6.1 2.4mL Injection
      9.6.2 10mL Injection
   9.7 Basis Point Share (BPS) Analysis by Type 
   9.8 Absolute $ Opportunity Assessment by Type 
   9.9 Market Attractiveness Analysis by Type
   9.10 North America Durvalumab Market Size Forecast by Applications
      9.10.1 Locally Advanced Urothelial Carcinoma
      9.10.2 Metastatic Urothelial Carcinoma
      9.10.3 Other
   9.11 Basis Point Share (BPS) Analysis by Applications 
   9.12 Absolute $ Opportunity Assessment by Applications 
   9.13 Market Attractiveness Analysis by Applications

Chapter 10 Europe Durvalumab Analysis and Forecast
   10.1 Introduction
   10.2 Europe Durvalumab Market Size Forecast by Country
      10.2.1 Germany
      10.2.2 France
      10.2.3 Italy
      10.2.4 U.K.
      10.2.5 Spain
      10.2.6 Russia
      10.2.7 Rest of Europe
   10.3 Basis Point Share (BPS) Analysis by Country
   10.4 Absolute $ Opportunity Assessment by Country
   10.5 Market Attractiveness Analysis by Country
   10.6 Europe Durvalumab Market Size Forecast by Type
      10.6.1 2.4mL Injection
      10.6.2 10mL Injection
   10.7 Basis Point Share (BPS) Analysis by Type 
   10.8 Absolute $ Opportunity Assessment by Type 
   10.9 Market Attractiveness Analysis by Type
   10.10 Europe Durvalumab Market Size Forecast by Applications
      10.10.1 Locally Advanced Urothelial Carcinoma
      10.10.2 Metastatic Urothelial Carcinoma
      10.10.3 Other
   10.11 Basis Point Share (BPS) Analysis by Applications 
   10.12 Absolute $ Opportunity Assessment by Applications 
   10.13 Market Attractiveness Analysis by Applications

Chapter 11 Asia Pacific Durvalumab Analysis and Forecast
   11.1 Introduction
   11.2 Asia Pacific Durvalumab Market Size Forecast by Country
      11.2.1 China
      11.2.2 Japan
      11.2.3 South Korea
      11.2.4 India
      11.2.5 Australia
      11.2.6 South East Asia (SEA)
      11.2.7 Rest of Asia Pacific (APAC)
   11.3 Basis Point Share (BPS) Analysis by Country
   11.4 Absolute $ Opportunity Assessment by Country
   11.5 Market Attractiveness Analysis by Country
   11.6 Asia Pacific Durvalumab Market Size Forecast by Type
      11.6.1 2.4mL Injection
      11.6.2 10mL Injection
   11.7 Basis Point Share (BPS) Analysis by Type 
   11.8 Absolute $ Opportunity Assessment by Type 
   11.9 Market Attractiveness Analysis by Type
   11.10 Asia Pacific Durvalumab Market Size Forecast by Applications
      11.10.1 Locally Advanced Urothelial Carcinoma
      11.10.2 Metastatic Urothelial Carcinoma
      11.10.3 Other
   11.11 Basis Point Share (BPS) Analysis by Applications 
   11.12 Absolute $ Opportunity Assessment by Applications 
   11.13 Market Attractiveness Analysis by Applications

Chapter 12 Latin America Durvalumab Analysis and Forecast
   12.1 Introduction
   12.2 Latin America Durvalumab Market Size Forecast by Country
      12.2.1 Brazil
      12.2.2 Mexico
      12.2.3 Rest of Latin America (LATAM)
   12.3 Basis Point Share (BPS) Analysis by Country
   12.4 Absolute $ Opportunity Assessment by Country
   12.5 Market Attractiveness Analysis by Country
   12.6 Latin America Durvalumab Market Size Forecast by Type
      12.6.1 2.4mL Injection
      12.6.2 10mL Injection
   12.7 Basis Point Share (BPS) Analysis by Type 
   12.8 Absolute $ Opportunity Assessment by Type 
   12.9 Market Attractiveness Analysis by Type
   12.10 Latin America Durvalumab Market Size Forecast by Applications
      12.10.1 Locally Advanced Urothelial Carcinoma
      12.10.2 Metastatic Urothelial Carcinoma
      12.10.3 Other
   12.11 Basis Point Share (BPS) Analysis by Applications 
   12.12 Absolute $ Opportunity Assessment by Applications 
   12.13 Market Attractiveness Analysis by Applications

Chapter 13 Middle East & Africa (MEA) Durvalumab Analysis and Forecast
   13.1 Introduction
   13.2 Middle East & Africa (MEA) Durvalumab Market Size Forecast by Country
      13.2.1 Saudi Arabia
      13.2.2 South Africa
      13.2.3 UAE
      13.2.4 Rest of Middle East & Africa (MEA)
   13.3 Basis Point Share (BPS) Analysis by Country
   13.4 Absolute $ Opportunity Assessment by Country
   13.5 Market Attractiveness Analysis by Country
   13.6 Middle East & Africa (MEA) Durvalumab Market Size Forecast by Type
      13.6.1 2.4mL Injection
      13.6.2 10mL Injection
   13.7 Basis Point Share (BPS) Analysis by Type 
   13.8 Absolute $ Opportunity Assessment by Type 
   13.9 Market Attractiveness Analysis by Type
   13.10 Middle East & Africa (MEA) Durvalumab Market Size Forecast by Applications
      13.10.1 Locally Advanced Urothelial Carcinoma
      13.10.2 Metastatic Urothelial Carcinoma
      13.10.3 Other
   13.11 Basis Point Share (BPS) Analysis by Applications 
   13.12 Absolute $ Opportunity Assessment by Applications 
   13.13 Market Attractiveness Analysis by Applications

Chapter 14 Competition Landscape 
   14.1 Durvalumab Market: Competitive Dashboard
   14.2 Global Durvalumab Market: Market Share Analysis, 2019
   14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.3.1 Medimmune (AstraZeneca)
Segments Covered in the Report
The global Durvalumab market has been segmented based on

By Types
  • 2.4mL Injection
  • 10mL Injection
By Applications
  • Locally Advanced Urothelial Carcinoma
  • Metastatic Urothelial Carcinoma
  • Other
Regions
  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa
Key Players
  • Medimmune (AstraZeneca)

Buy Report